Long-term efficacy, safety, and tolerability of a subcutaneous immunoglobulin 16.5% (cutaquig(®)) in the treatment of patients with primary immunodeficiencies

A prospective study and its long-term extension examined whether weekly treatment of patients with primary immunodeficiencies (PIDs) with a 16.5% subcutaneous immunoglobulin (SCIg; cutaquig(®)) confers acceptable efficacy, safety, and tolerability over a follow-up of up to 238 weeks (>4 years). S...

Descripción completa

Detalles Bibliográficos
Autores principales: Kobayashi, Roger H, Litzman, Jiří, Melamed, Isaac, Mandujano, J Fernando, Kobayashi, Ai Lan, Ritchie, Bruce, Geng, Bob, Atkinson, T Prescott, Rehman, Syed, Höller, Sonja, Turpel-Kantor, Eva, Kreuwel, Huub, Speer, J C, Gupta, Sudhir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Editors’ Choice
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9750824/
https://www.ncbi.nlm.nih.gov/pubmed/36208448
http://dx.doi.org/10.1093/cei/uxac092

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9750824/
https://www.ncbi.nlm.nih.gov/pubmed/36208448
http://dx.doi.org/10.1093/cei/uxac092

Ejemplares similares